진행성 비소세포 폐암 환자에서 젬사이타빈과 시스플라틴의 3주 주기 복합 항암 화학요법
Three-week Scheduled Combination Chemotherapy of Gemcitabine and Cisplatin in advanced Non-small Cell Lung Cancer
비소세포폐암 폐암환자 젬사이타빈 시스플라틴 항암화학요법;
- 원문 URL
Background: The combination chemotherapy of gemcitabine and cisplatin (GC) has proven effective in the treatment of advanced non-small cell lung cancer (NSCLC). However, the optimal schedule for administration of the two drugs has not yet been determined. I therefore started a phase Ⅱ trial to evaluate efficacy, toxicity and dose intensity (DI) for three-week scheduled chemotherapy of GC. Method: Between October 2000 and March 2003, a total of 56 patients with stage ⅢB and Ⅳ NSCLC enrolled in this study. Treatment schedule consisted of gemcitabine 1200mg/㎡ i.v. on day 1 and 8 and cisplatin 80 mg/㎡ i.v. on day 1 of each chemotherapy cycle followed by two weeks of rest. Results: Forty-eight patients were evaluable in resoponse and toxoicities in this study. The median DI was 529 mg/㎡/week for gemcitabine (66 %) and 22 mg/㎡/week for cisplatin (83%). Partial response were observed in 23 patients. The overall response rate was 47.8 % (95% CI, 33.6∼61.9%). Anemia and thrombocytopenia as the grade 3 to 4 toxicity were 8.3% and 8.3% respectively. The median survival time was 11.78 months (95% CI, 8.59∼14.97 months). No significant differences in response rate were observed according to sex, age, histology and DI of GC Conclusion: The 3-week scheduled combination chemotherapy of GC has a relatively high activity(overall response rate: 47.8%) with acceptable toxicities in patients with advanced NSCLC.